... n the Treatment of Asyeptomatic PCP: A Pilot Study Assessing the ... Cryptococcal Accrual) Reningitia ACTG 060 Withdrawn acte 070 Open ACTG ...

... values for what is not allowed under the study and what makes an individual ... has three levels: open, closed, and completed. This is one of the most ...

... possible alternate to cisplatin, but an MRC randomised study of 130 patients ... remain standard therapy and that carboplatin should only be used in ...

... 7). ° Cessation After Diagnosis of Lung Cancer Two studies examined the relationship between smoking status and treatment out- come of patients with small cell lung ...

... more drug becomes available, we will initiate additional studies to evaluate other regimens, patient populations, disease status, combination therapy and so on. We are collaborating with the ...

... more drug becomes available, we will initiate additional studies to evaluate other regimens, patient populations, disease status, combination therapy and so on. We are collaborating with the ...

... use, ADRs, FDA licensing - INDAs and NDAs, etc.); status of experimental therapy for each drug under study (number of subjects enrolled, preliminary findings, etc.); list ...

... protocols, but there are is only one primary therapeutic protocol for children. And that was just recently closed to accrual. So, at this point in time, there are ...

... vs. dapsone vs. trimethoprim/sulfamethoxazole. e Nearly completed accrual for a secondary PCP prophylaxis study of aerosolized pentamidine vs. trimethoprim/sulfamethoxazole. Initial and salvage acute therapies for CMV are also being comprehensively developed through ...

... vs. dapsone vs. trimethoprim/sulfamethoxazole. e Nearly completed accrual for a secondary PCP prophylaxis study of aerosolized pentamidine vs. trimethoprim/sulfamethoxazole. Initial and salvage acute therapies for CMV are also being comprehensively developed through ...